证券代码：300110 证券简称：华仁药业 公告编号：2025-069 二、董事会会议审议情况 全体与会董事经认真审议和表决，形成以下决议： （一）审议通过《2025 年第三季度报告》 经审议，全体董事认为公司编制《2025 年第三季度报告》的程序符合有关法 律法规和中国证监会的规定，报告内容真实、准确、完整地反映了公司 2025 年第 三季度的财务状况和经营情况，不存在任何虚假记载、误导性陈述或重大遗漏。 公司《2025 年第三季度报告》的具体内容详见公司同日披露在中国证监会指 定创业板信息披露网站巨潮资讯网的相关公告（公告编号：2025-070）。 本议案已经公司董事会审计委员会审议通过。 华仁药业股份有限公司 第八届董事会第十二次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载，误导性陈述或重大遗漏。 一、董事会会议召开情况 华仁药业股份有限公司（以下简称"公司"）第八届董事会第十二次会议于 2025 年 10 月 29 日以现场和网络会议相结合的形式召开。会议通知已于 2025 年 10 月 17 日以电子邮件方式发给各位董事。会议由代行董事长侯瑞鹏先生召集并 主 ...

Revenue and Profitability - Revenue for Q3 2025 reached ¥352,374,010.10, an increase of 16.62% compared to the same period last year[2] - Net profit attributable to shareholders decreased by 22.72% to ¥17,246,910.68 in Q3 2025, and by 42.87% to ¥54,579,793.85 for the year-to-date[2] - Basic earnings per share for Q3 2025 were ¥0.0146, down 22.75% year-on-year[2] - Total operating revenue for the current period is RMB 976,270,444.55, a decrease of 9.07% compared to RMB 1,073,621,963.53 in the previous period[21] - Net profit for the period was ¥57,398,016.43, down from ¥100,471,124.16, representing a decline of about 43%[23] - Basic and diluted earnings per share decreased to ¥0.0462 from ¥0.0808, a drop of approximately 42.5%[23] Assets and Liabilities - Total assets as of September 30, 2025, were ¥3,396,808,707.61, a decrease of 0.91% from the end of the previous year[2] - Total assets decreased to RMB 3,396,808,707.61 from RMB 3,428,120,079.39, a decline of 0.9%[19] - Total liabilities decreased to RMB 1,970,961,247.11 from RMB 2,054,191,740.04, a reduction of 4.0%[19] - Non-current assets decreased slightly to RMB 2,234,426,391.53 from RMB 2,243,141,469.80, a decline of 0.3%[18] - The total equity attributable to the parent company increased to RMB 1,355,366,082.86 from RMB 1,300,786,289.01, a growth of 4.2%[19] Cash Flow and Financial Activities - Cash flow from operating activities for the year-to-date was ¥256,623,163.38, down 10.08% compared to the same period last year[2] - Cash flow from operating activities generated ¥256,623,163.38, compared to ¥285,386,815.04 in the previous period, a decrease of about 10%[25] - Cash and cash equivalents increased to RMB 222,890,633.82 from RMB 163,813,254.90, representing a growth of 36%[18] - Cash and cash equivalents at the end of the period increased to ¥186,178,965.82 from ¥119,922,385.96, reflecting a net increase of approximately 55.4%[26] - The net cash flow from financing activities for the year-to-date was -¥175,892,477.20, a decrease of 51.18% compared to the previous year[10] - Financing activities produced a net cash outflow of ¥175,892,477.20, an improvement from an outflow of ¥360,267,179.13 in the previous period[25] Inventory and Prepayments - Inventory decreased by 20.64% to ¥252,561,995.35, attributed to improved inventory management[6] - Inventory decreased significantly to RMB 252,561,995.35 from RMB 318,237,397.12, a reduction of 20.6%[18] - The company reported a significant increase in prepayments by 63.04% to ¥33,075,466.47, mainly due to increased operational prepayments[6] Financial Performance Metrics - Financial expenses decreased by 21.95% to ¥33,783,971.27 for the year-to-date, primarily due to reduced interest expenses from loan scale compression[8] - The weighted average return on equity for Q3 2025 was 1.28%, an increase of 0.47% from the previous year[2] - Tax expenses decreased to ¥5,879,952.99 from ¥13,939,611.92, a reduction of approximately 57.8%[22] - Other income increased to ¥2,180,154.49 from ¥582,194.48, marking a significant rise of about 274%[22] - The company reported a credit impairment loss of ¥-13,968,652.22, worsening from ¥-913,335.01 in the previous period[22]

Group 1 - The core point of the article is that Huaren Pharmaceutical has received approval from the National Medical Products Administration for its product "Nafamostat Mesilate Injection" [1] - Huaren Pharmaceutical's revenue composition for the first half of 2025 shows that the pharmaceutical industry accounts for 95.79% and the pharmaceutical commerce accounts for 4.21% [1] - As of the report date, Huaren Pharmaceutical has a market capitalization of 4 billion yuan [1] Group 2 - The article mentions that Chinese innovative drugs have generated 80 billion USD in overseas licensing this year [1] - It highlights a conversation with Lu Gang, a partner at Chuangdong Investment, discussing the hot secondary market in biomedicine while the primary market faces fundraising challenges [1]

关于全资子公司盐酸奈福泮注射液取得 药品注册证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，华仁药业股份有限公司（以下简称"公司"）全资子公司安徽恒星制药 有限公司（以下简称"安徽恒星制药"）收到国家药品监督管理局核准签发的"盐 酸奈福泮注射液"的《药品注册证书》，具体情况公告如下： 证券代码：300110 证券简称：华仁药业 公告编号：2025-068 华仁药业股份有限公司 一、药品基本情况 1．药品名称 药品通用名称：盐酸奈福泮注射液 英文名/拉丁名：Nefopam Hydrochloride Injection 2．剂型：注射剂 3．申请事项：药品注册（境内生产） 根据《中华人民共和国药品管理法》及有关规定，经审查，本品符合药品注 册的有关要求，批准注册，发给药品注册证书。质量标准、说明书、标签及生产 工艺照所附执行。药品生产企业应当符合药品生产质量管理规范要求方可生产销 售。 名称：安徽恒星制药有限公司 地址：合肥市包河工业区纬五路 15 号 13．药品批准文号：国药准字 H20255748 14．药品批准文号有效期：至 2030 年 ...

Group 1 - The core viewpoint of the news is that Huaren Pharmaceutical's stock performance and financing activities indicate a stable but cautious market position, with significant changes in revenue and profit margins reported in recent financial results [1][2]. Group 2 - As of October 23, Huaren Pharmaceutical's stock price remained unchanged at 0.00%, with a trading volume of 60.76 million yuan. The financing buy-in amount was 9.08 million yuan, while the financing repayment was 11.02 million yuan, resulting in a net financing buy-in of -1.94 million yuan [1]. - The total balance of margin trading for Huaren Pharmaceutical reached 256 million yuan, accounting for 6.35% of its market capitalization, which is above the 60th percentile level over the past year, indicating a relatively high financing level [1]. - The company has not engaged in any short selling activities on October 23, with no shares sold or repaid, and the short selling balance also stood at zero [1]. - Huaren Pharmaceutical's main business revenue composition includes: basic infusion (40.63%), peritoneal dialysis fluid (34.90%), therapeutic preparations (14.92%), medical devices (8.14%), and others (1.41%) [1]. Group 3 - As of October 10, the number of shareholders for Huaren Pharmaceutical was 40,700, an increase of 0.49% from the previous period, while the average circulating shares per person decreased by 0.49% to 29,013 shares [2]. - For the first half of 2025, Huaren Pharmaceutical reported a revenue of 624 million yuan, a year-on-year decrease of 19.13%, and a net profit attributable to shareholders of 37.33 million yuan, down 49.01% year-on-year [2]. Group 4 - Since its A-share listing, Huaren Pharmaceutical has distributed a total of 294 million yuan in dividends, with cumulative distributions of 49.65 million yuan over the past three years [3].

Core Viewpoint - Huaren Pharmaceutical (300110) announced the appointment of Mr. Li Jian as a non-independent director of the company's eighth board of directors [1] Group 1 - The company has agreed to the re-election of Mr. Li Jian [1]

证券代码：300110 证券简称：华仁药业 公告编号：2025-066 公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载，误导性陈述或重大遗漏。 特别提示： 1、本次股东会无变更、否决提案的情况； 华仁药业股份有限公司 2025 年第二次临时股东会决议公告 2、本次股东会不涉及变更以往股东会已通过的决议。 一、会议召开及召集情况 1、会议通知情况：华仁药业股份有限公司（以下简称"公司"）2025年9月29 日以董事会公告方式向全体股东发出召开2025年第二次临时股东会的通知。 2、会议召开时间： （1）现场会议召开时间：2025年10月15日14:00。 （2）网络投票时间：通过深圳证券交易所交易系统进行网络投票的具体时 间为：2025年10月15日上午9:15-9:25，9:30-11:30和下午13:00-15:00；通过深圳 证券交易所互联网投票系统投票的具体时间为：2025年10月15日上午9:15-下午 15:00期间的任意时间。 3、会议召开地点：山东省青岛市高科技工业园株洲路187号公司会议室。 4、会议召集人：公司董事会。 5、会议召开方式：采取现场投票与网络投票相结合的 ...

北京植德（青岛）律师事务所 关于华仁药业股份有限公司 2025 年第二次临时股东会的 法律意见书 北京植德（青岛）律师事务所 关于华仁药业股份有限公司 2025 年第二次临时股东会的 法律意见书 植德青（会）字[2025]0003 号 致：华仁药业股份有限公司（华仁药业/贵公司） 北京植德（青岛）律师事务所（以下简称"本所"）接受贵公司的委托，指 派律师出席并见证贵公司 2025 年第二次临时股东会（以下简称"本次会议"）。 植德青（会）字[2025]0003 号 二〇二五年十月 山东省青岛市崂山区香岭路 1 号资源博雅广场 4 号楼 10 层 邮编：266000 10th Floor, Building 4, Resources Boya Plaza, No.1 Xiangling Road, Laoshan District, Qingdao City, Shandong Province 266000 P.R.C www.meritsandtree.com 本所律师参加本次会议进行见证，并根据《中华人民共和国公司法》（以下 简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、 《上 ...

证券代码：300110 证券简称：华仁药业 公告编号：2025-067 李健先生，1982 年 10 月出生，中国国籍，中共党员，无境外永久居留权， 医学博士，副主任医师。曾先后供职于总后勤部青藏兵站部、解放军总医院海南 分院、解放军总医院、解放军总医院第一医学中心等单位的多个医疗和管理岗位， 现任华仁药业董事、总裁。 华仁药业股份有限公司 李健先生未持有公司股份，与持有公司 5%以上股份的股东、实际控制人、 公司其他董事、高级管理人员不存在关联关系；不存在《公司法》第一百七十八 条、《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运 作》第 3.2.3 条、第 3.2.4 条规定的情形；未受过中国证监会及其他有关部门的处 罚和证券交易所纪律处分，不存在因涉嫌犯罪被司法机关立案侦查或者涉嫌违法 违规被中国证监会立案稽查尚未有明确结论的情形，未曾被中国证监会在证券期 货市场违法失信信息公开查询平台公示或者被人民法院纳入失信被执行人名单； 符合有关法律法规、规范性文件等规定的任职条件。 关于完成补选第八届董事会非独立董事的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 ...

Core Viewpoint - The announcement from Huaren Pharmaceutical indicates that shareholder Hongta Innovation has reduced its stake in the company by selling 11.82 million shares at an average price of 3.38 yuan, resulting in a reduction of ownership to 4.72% [1] Summary by Relevant Sections - **Shareholder Activity** - Hongta Innovation sold a total of 11.82 million shares through centralized bidding from August 26, 2025, to January 10, 2025 [1] - The average selling price was 3.38 yuan per share, leading to a total reduction in ownership by 1.00% [1] - After the sale, Hongta Innovation holds 55.8231 million shares, which is now below the 5% threshold for significant shareholders [1]